Early Insulin Sensitization by Tirzepatide in Japanese Patients with Obesity and Type 2 Diabetes: Insights from a Hyperinsulinaemic-Euglycaemic Clamp Study
Highlight
1. Tirzepatide at a low dose of 5 mg weekly significantly increased insulin sensitivity measured by glucose infusion rate (GIR) within 12 weeks.
2. HbA1c and body weight notably decreased alongside reductions in fat mass and glucagon levels.
3. Improvement in insulin sensitivity occurred independent of weight loss, suggesting direct metabolic effects.
4. No significant correlations were found between GIR changes and typical metabolic markers, indicating a complex mechanism of action.
Study Background and Disease Burden
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.